Ranbaxy Laboratories Ltd (RANB.NS)
394.30INR
3:59pm IST
Rs-36.75 (-8.53%)
Rs471.50
Rs425.00
Rs425.40
Rs384.70
3,387,471
977,285
Rs578.40
Rs370.80
RANB.NS
About
Overall
| Beta: | 1.23 |
| Market Cap (Mil.): | Rs182,377.70 |
| Shares Outstanding (Mil.): | 423.10 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| RANB.NS | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 19.82 | 35.19 | 35.42 |
| EPS (TTM): | 21.75 | -- | -- |
| ROI: | 14.50 | 19.50 | 18.86 |
| ROE: | 26.55 | 20.27 | 19.73 |
Ranbaxy shares slump after Daiichi Sankyo says misled
MUMBAI - Ranbaxy Laboratories Ltd slumped as much as 9.37 percent on Thursday after majority shareholder Daiichi Sankyo Co said it believes former shareholders of the Indian company hid information regarding U.S. regulatory probes.
MARKET EYE-Indian shares fall; Ranbaxy, L&T slump
* India's main BSE index falls 0.66 percent and the broader NSE index is down 0.8 percent, heading towards their fourth consecutive session of declines. * Asian stocks slid and the dollar rose to a 4-1/2 year high after Fed Chairman Ben Bernanke's remarks sparked worries of a reduction in U.S. monetary stimulus and after data showed China's factory activity shrank for the first time in seven months in May. * Ranbaxy Laboratories Ltd slumps 6 percent after majority shareholder Daiichi Sankyo
Ranbaxy shares slump after Daiichi Sankyo says misled over probes
MUMBAI, May 23 - Ranbaxy Laboratories Ltd slumped as much as 6.6 percent on Thursday after majority shareholder Daiichi Sankyo Co said it believes former shareholders of the Indian company hid information regarding U.S. regulatory probes.
Daiichi Sankyo says it was misled over Ranbaxy probes
MUMBAI - Japanese drugmaker Daiichi Sankyo Co, which bought control of Ranbaxy Laboratories in 2008, said it believes unnamed former shareholders of the company hid information regarding U.S. regulatory probes into Ranbaxy.
Ranbaxy recovers; U.S. fine overhang seen ending
Reuters Market Eye - Ranbaxy Laboratories Ltd shares recovered on Tuesday as U.S. fine overhang was seen ending.
Ranbaxy recovers; U.S. fine overhang seen ending
Reuters Market Eye - Shares in Ranbaxy Laboratories Ltd gain 3 percent, after earlier declining as much as 4.2 percent, as traders call those falls extensive.
MARKET EYE-India's Ranbaxy recovers; U.S. fine overhang seen ending
* Shares in Ranbaxy Laboratories Ltd gain 3 percent, after earlier declining as much as 4.2 percent, as traders call those falls extensive. * The Indian generic drugmaker slumped earlier, a day after pleading guilty to U.S. felony charges related to drug safety and agreed to pay $500 million in civil and criminal fines. * However, analysts note that Ranbaxy in December 2011 set aside $500 million to resolve the potential criminal and civil liabilities related to the investigation by the U.S. g
Ranbaxy shares slump on $500 million fine to settle US drug safety charges
MUMBAI - Ranbaxy Laboratories Ltd shares fell 3.4 percent in pre-open trading on Tuesday after the Indian generic drugmaker pleaded guilty to U.S. felony charges related to drug safety and will pay $500 million in civil and criminal fines.
Ranbaxy shares slump on $500 mln fine to settle US drug safety charges
MUMBAI, May 14 - Ranbaxy Laboratories Ltd shares fell 3.4 percent in pre-open trading on Tuesday after the Indian generic drugmaker pleaded guilty to U.S. felony charges related to drug safety and will pay $500 million in civil and criminal fines.
Ranbaxy pleads guilty, to pay $500 mln in settlement
REUTERS - Generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the U.S. Department of Justice.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
